Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial
- DOI
- 10.1016/j.clbc.2016.02.003
- Published
- 2016-06
- Container
- Clinical Breast Cancer
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.clbc.2016.02.003,
title = {Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial},
author = {Denise A. Yardley and Natalie Dickson and David Drosick and Chris Earwood and Roger Inhorn and Patrick Murphy and John D. Hainsworth},
year = {2016},
journal = {Clinical Breast Cancer},
doi = {10.1016/j.clbc.2016.02.003},
url = {https://doi.org/10.1016/j.clbc.2016.02.003}
}RIS
TY - JOUR TI - Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial AU - Denise A. Yardley AU - Natalie Dickson AU - David Drosick AU - Chris Earwood AU - Roger Inhorn AU - Patrick Murphy AU - John D. Hainsworth PY - 2016 JO - Clinical Breast Cancer DO - 10.1016/j.clbc.2016.02.003 UR - https://doi.org/10.1016/j.clbc.2016.02.003 ER -
APA
Yardley, D. A., Dickson, N., Drosick, D., Earwood, C., Inhorn, R., Murphy, P., & Hainsworth, J. D. (2016). Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2016.02.003
Source records
- crossref · retrieved 2026-09-26T19:53:10.447Z